Tags

Type your tag names separated by a space and hit enter

Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
Life Sci. 2020 Dec 15; 263:118588.LS

Abstract

The severe acute respiratory syndrome-novel coronavirus mediated COVID-19 has been recently declared a pandemic by the World Health Organization. The primary target of the SARS-CoV-2 virus is the human lungs governed by the ACE-2 receptor of epithelial type II cells/endothelial cells, which promote modulation of the immune response of host cells through generating cytokine storm, inflammation, severe pneumonia symptoms, and secondary complications such as acute respiratory distress syndrome. Although numerous antiviral and anti-parasitic drugs are under clinical trials to combat this pandemic, to date, neither a specific treatment nor any successful vaccine has been established, urging researchers to identify any potential candidate for combating the disease. Mesenchymal stem cells own self-renewal, differentiation, homing, immunomodulation and remains unaffected by the coronavirus on the virtue of the absence of ACE-2 receptors, indicating that MSC's could be used an ameliorative approach for COVID-19. MSCs have shown to combat the disease via various pathways such as repairing the lung epithelial and endothelial cells, reducing hyperimmune response, maintaining the renin-angiotensin system. Although MSCs-based treatment approaches for COVID-19 is still under consideration with limited data, many human clinical trials of MSC's has been initiated to explore their potential for COVID 19 treatment. The current review summarizes and emphasizes on how MSC's modulate the immune response, can repair the lungs from the impact of the virus, and various aspects of MSC's as a remedial source for COVID-19, to provide better insight for biomedical researchers and for those who are fascinated by stem cells as a therapeutic approach.

Authors+Show Affiliations

Centre for Medical Biotechnology, Maharshi Dayanand University Rohtak, 124001, India.Centre for Medical Biotechnology, Maharshi Dayanand University Rohtak, 124001, India.Centre for Medical Biotechnology, Maharshi Dayanand University Rohtak, 124001, India.Centre for Medical Biotechnology, Maharshi Dayanand University Rohtak, 124001, India. Electronic address: bhardwajrashmi3@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33049279

Citation

Yadav, Pooja, et al. "Mesenchymal Stem Cell Immunomodulation and Regeneration Therapeutics as an Ameliorative Approach for COVID-19 Pandemics." Life Sciences, vol. 263, 2020, p. 118588.
Yadav P, Vats R, Bano A, et al. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci. 2020;263:118588.
Yadav, P., Vats, R., Bano, A., & Bhardwaj, R. (2020). Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sciences, 263, 118588. https://doi.org/10.1016/j.lfs.2020.118588
Yadav P, et al. Mesenchymal Stem Cell Immunomodulation and Regeneration Therapeutics as an Ameliorative Approach for COVID-19 Pandemics. Life Sci. 2020 Dec 15;263:118588. PubMed PMID: 33049279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. AU - Yadav,Pooja, AU - Vats,Ravina, AU - Bano,Afsareen, AU - Bhardwaj,Rashmi, Y1 - 2020/10/10/ PY - 2020/08/31/received PY - 2020/10/02/revised PY - 2020/10/07/accepted PY - 2020/10/14/pubmed PY - 2020/12/16/medline PY - 2020/10/13/entrez KW - ACE-2 receptor KW - Acute respiratory distress syndrome KW - COVID-19 KW - Immunomodulation KW - Lung fibrosis KW - Mesenchymal stem cells KW - SARS-CoV-2 SP - 118588 EP - 118588 JF - Life sciences JO - Life Sci VL - 263 N2 - The severe acute respiratory syndrome-novel coronavirus mediated COVID-19 has been recently declared a pandemic by the World Health Organization. The primary target of the SARS-CoV-2 virus is the human lungs governed by the ACE-2 receptor of epithelial type II cells/endothelial cells, which promote modulation of the immune response of host cells through generating cytokine storm, inflammation, severe pneumonia symptoms, and secondary complications such as acute respiratory distress syndrome. Although numerous antiviral and anti-parasitic drugs are under clinical trials to combat this pandemic, to date, neither a specific treatment nor any successful vaccine has been established, urging researchers to identify any potential candidate for combating the disease. Mesenchymal stem cells own self-renewal, differentiation, homing, immunomodulation and remains unaffected by the coronavirus on the virtue of the absence of ACE-2 receptors, indicating that MSC's could be used an ameliorative approach for COVID-19. MSCs have shown to combat the disease via various pathways such as repairing the lung epithelial and endothelial cells, reducing hyperimmune response, maintaining the renin-angiotensin system. Although MSCs-based treatment approaches for COVID-19 is still under consideration with limited data, many human clinical trials of MSC's has been initiated to explore their potential for COVID 19 treatment. The current review summarizes and emphasizes on how MSC's modulate the immune response, can repair the lungs from the impact of the virus, and various aspects of MSC's as a remedial source for COVID-19, to provide better insight for biomedical researchers and for those who are fascinated by stem cells as a therapeutic approach. SN - 1879-0631 UR - https://www.unboundmedicine.com/medline/citation/33049279/Mesenchymal_stem_cell_immunomodulation_and_regeneration_therapeutics_as_an_ameliorative_approach_for_COVID_19_pandemics_ DB - PRIME DP - Unbound Medicine ER -